Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 514

Results For "ED"

7945 News Found

Alembic receives EIR for oncology injectable formulation facility at Panelav
Drug Approval | December 12, 2022

Alembic receives EIR for oncology injectable formulation facility at Panelav

This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA


Zydus receives USFDA approval to market Silodosin and Pregabalin capsules
Drug Approval | December 12, 2022

Zydus receives USFDA approval to market Silodosin and Pregabalin capsules

Silodosin capsules treat signs and symptoms of an enlarged prostate gland


National Health Ministers’ Conclave concludes in Varanasi
Policy | December 12, 2022

National Health Ministers’ Conclave concludes in Varanasi

They also released the Operational Guidelines for Wellness activities at AB-HWCs


Progress under “PM Surakshit Matritva Abhiyan”
Policy | December 12, 2022

Progress under “PM Surakshit Matritva Abhiyan”

Since inception, more than 3.6 crore pregnant women have received comprehensive ANC under this programme across all states and UTs


Steps taken by Govt. to support diabetes patients
Policy | December 12, 2022

Steps taken by Govt. to support diabetes patients

As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years


PM lays foundation stone for National Institute for One Health in Nagpur
Policy | December 12, 2022

PM lays foundation stone for National Institute for One Health in Nagpur

The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents


Entod Pharmaceuticals to launch GLO division
News | December 12, 2022

Entod Pharmaceuticals to launch GLO division

This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma


GSK’s new data underscore important responses with momelotinib for myelofibrosis patients
Diagnostic Center | December 12, 2022

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response


Global pacemakers market set to grow at 5.4% CAGR over next 3 years: GlobalData
News | December 12, 2022

Global pacemakers market set to grow at 5.4% CAGR over next 3 years: GlobalData

GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.


Merck begins Tender Offer to acquire Imago BioSciences
News | December 12, 2022

Merck begins Tender Offer to acquire Imago BioSciences

As a result, Imago will become a subsidiary of Merck.